Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11447079 | 0.78 | ALDH1A1 (0.49) | KDM1AMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16884331 | 0.77 | TRPV6 (0.56) | TRPV6MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3363241 | 0.76 | ALDH1A1 (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6329441 | 0.76 | MEN1 (0.46) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL3361535 | 0.75 | KDM1A (0.59) | KDM1AMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8866289 | 0.75 | SIGMAR1 (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL3360521 | 0.74 | TRPV6 (0.56) | KDM1ATRPV6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16884330 | 0.74 | TRPV6 (0.56) | TRPV6MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15029146 | 0.74 | MEN1 (0.61) | TRPV6MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11688986 | 0.74 | P2RX7 (0.63) | KDM1ATRPV6MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239131-A1 | NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-11-01 | — | — | EP | claimed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | claimed |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2016-03-24 | — | — | US | claimed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | claimed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | claimed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| EP-3239131-A1 | NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | HAVCR2, MAVS, ANTXR2 | KDM1A 3968/4885TRPV6 874/4885MEN1 3020/4885 |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | HAVCR2, MAVS, ANTXR2 | KDM1A 3633/4885TRPV6 1076/4885MEN1 2389/4885 |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | HAVCR2, HDLBP, HSP90B1 | KDM1A 3942/4885TRPV6 3648/4885MEN1 3879/4885 |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | HAVCR2, MAVS, ANTXR2 | KDM1A 3633/4885TRPV6 1076/4885MEN1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.